Intermediate · 12-24+ weeks
Retatrutide Triple-Agonist Titration
Dose escalation schedule based on Phase 2 trial data. Triple-agonist (GLP-1/GIP/glucagon) for metabolic optimization. Start at 1mg weekly, escalate by 2mg every 4 weeks to target dose of 8-12mg.
- Type
- single
- Source
- evidence-based
- Pattern
- Continuous — stopping leads to weight regain
Compounds
Retatrutide
SC · Any consistent day/time weekly. Target dose 8mg after escalation.
SC · Any consistent day/time weekly. Target dose 8mg after escalation.
8 mg
weekly
weekly
Phases
Initiation
Weeks 1-4
Weeks 1-4
1
1mg weekly — conservative start for GI tolerance
1mg weekly — conservative start for GI tolerance
Step 2
Weeks 5-8
Weeks 5-8
2
2mg weekly
2mg weekly
Step 3
Weeks 9-12
Weeks 9-12
4
4mg weekly — first meaningful therapeutic dose
4mg weekly — first meaningful therapeutic dose
Target Dose
Weeks 13+
Weeks 13+
8
8mg weekly — target dose for most researchers
8mg weekly — target dose for most researchers
Notes
DOSE ESCALATION IS MANDATORY — never start above 1-2mg. GI side effects (nausea, diarrhea) worst during escalation. DO NOT combine with tirzepatide (overlapping mechanisms). Subscription-native product — escalating vial needs monthly.
Source notes
Phase 2 trial NEJM 2023: ~24% body weight loss at highest dose over 48 weeks. r/Retatrutide: protocols mirror Phase 2 trial. Phase 3 completion expected early 2026.
For research and educational use only. This content is not medical advice.